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Abstract 
 
New psychoactive substances (NPS) are a heterogeneous group of substances. 
They are associated with a number of health and social harms on an individual and 
societal level. NPS toxicity and dependence syndromes are recognised in primary 
care, emergency departments, psychiatric inpatient and community care settings. 
One pragmatic classification system is to divide NPS into one of four groups: 
synthetic stimulants, synthetic cannabinoids, synthetic hallucinogens and synthetic 
depressants (which include synthetic opioids and benzodiazepines). We review 
these four classes of NPS, including their chemical structures, mechanism of action, 
modes of use, intended intoxicant effects, and their associated physical and mental 
health harms. The current challenges faced by laboratory testing for NPS are also 
explored, in the context of the diverse range of NPS currently available, rate of 
production and emergence of new substances, the different formulations, and 
methods of acquisition and distribution. 
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Introduction 
New psychoactive substances (NPS) are a complex and diverse group of 
substances often known as either designer or synthetic drugs, or by the more 
popular but misleading colloquial term of “legal highs”1,2. They tend to be either 
analogues of existing controlled drugs and pharmaceutical products or newly 
synthesised chemicals, created to mimic the actions and psychoactive effects of 
licensed medicines and other controlled substances3-5. By their number, nature and 
composition, NPS pose significant challenges for drug consumers, clinicians – both 
in drug services and more broadly - researchers, forensic toxicologists, healthcare 
systems and drug control policy globally, and have been described as a “growing 
worldwide epidemic” 6,7. 
 
The United Nations Office for Drugs and Crime (UNODC) has defined NPS as 
“substances of abuse, either in a pure form or a preparation, that are not controlled 
by the 1961 Single Convention on Narcotic Drugs or the 1971 Convention on 
Psychotropic Substances, but which may pose a public health threat”8. However, 
definitions of NPS can vary between countries, reflecting differences in national 
legislation, rather than pharmacological or structural classification. Although some 
former NPS have been subject to international control under the UN Conventions 
(e.g. mephedrone in 2015; the synthetic cannabinoid ADB-FUBINACA in 2019), 
different approaches have been taken to legal control at national level9-11. This has 
included the use of existing controlled drug legislation, new NPS-specific legislation, 
or extension of generic public health and medicines legislation. In the United 
Kingdom, for example, the Psychoactive Substances Act 2016 introduced legislation 
which made it an offence to produce, supply, offer to supply, possess with intent to 
supply, possess on custodial premises, import or export psychoactive substances, 
but did not make it an offence to possess for personal use outside of a custodial 
setting12. In principle this created a “blanket ban” of all current and future NPS (with 
certain exemptions). However, the legislation has been criticised for the imprecise 
definition of psychoactivity, its blanket nature covering compounds with quite 
differing harm profiles, difficulties in enforcement, and exemptions which meant that 
popular NPS such as nitrous oxide can still be purchased13-15. Early evaluation of the 
Act suggested that whilst the availability of NPS had decreased, there was no 
evidence of a reduction in NPS-related harms16. 
By 2018, a total of 892 individual NPS, reported by 119 countries, were being 
monitored by the UNODC early warning system17 and by the end of 2018, over 730 
NPS had been notified to the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA)18. The rapid proliferation at which new NPS have emerged on 
the global drugs market is unparalleled19 and it was estimated that at its peak in 
2015, new NPS appeared at a rate of at least one new substance per week20. The 
number of new NPS detections has decreased in recent years, and in addition, the 
nature of the market has changed, with a relative decrease in the number of new 
stimulants and synthetic cannabinoids detected, and an increase in the numbers of 
new opioids and benzodiazepines available18. The rapidly changing profile of the 
NPS market raises concerns over uncertainty and ambiguity regarding their 
chemical, metabolic and toxicity profiles, and the associated physical, social, and 
mental health harms21-23. 
 
Despite a large number of NPS being detected and actively monitored, estimates of 
general population use are relatively low compared to other type of controlled drugs, 
and use has fallen over the previous five years as result of factors such as legal 
control, market dynamics, substance trends and fashions, and changes in the 
availability of other controlled drugs24. NPS epidemiology is under-developed, and 
differences in definition and methodologies means that it is difficult to gain accurate 
estimates of use. The 2018/19 Crime Survey for England and Wales (CSEW) 
reported around 0.5 per-cent of adults aged 16 to 59 years (approximately 152,000 
people) had used NPS in the last year, and that around half of all NPS users were 
aged 16 to 24 years (encompassing approximately 86,000 young adults). Regarding 
frequency of use, of those who had consumed any NPS in the last year, about half 
had consumed at least twice that year, around one in four had used NPS two or 
more times a month and around eight per cent had used NPS daily25. Whilst 
individual NPS are not included in the CSEW, the most popular forms of substance 
were powders, crystals or tablets (31.0%); herbal smoking mixtures (24.1%); liquids 
(17.9%); or “another substance” (31.0%). Prevalence of nitrous oxide (“laughing 
gas”) has remained relatively high and stable over the past few years (despite legal 
control in 2016), and  2.3% of 16-59 year olds and 8.7% of 16-24 year olds report 
use in the previous year. Amongst 16-24 year olds, nitrous oxide is now the second 
most prevalent drug after cannabis (reported by 17.3% of 16-24 year olds)25. 
Although research suggests that NPS are associated with harms in key populations 
such as people who are homeless or prisoners26, there are no robust estimates of 
levels of use. For example, the 2018/19 Crime Survey for England and Wales 
described above is based on self-reporting by users. Data on adult drug treatment in 
England suggests that whilst there has been a recent increase in presentations 
(1,223 in 2018 to 1,363 in 2019; 11% increase), this was largely in service users 
taking NPS alongside opioids (and not solely NPS); it only represents 1% of all 
service users in treatment; and numbers have fallen from a peak in 2015/16 (2,042; 
a 33% decrease)27. The Office for National Statistics (ONS) reported that there were 
125 deaths registered in England and Wales in 2018 where NPS were mentioned on 
the death certificate. Although this represented only 2.9% of all drug related 
poisonings, it was the highest number yet recorded28. 
 
The term new psychoactive substance is a legal definition and there is no universally 
agreed way to categorise NPS29. Traditionally established recreational drugs and 
NPS have been functionally categorised into three broad categories (stimulants, 
hallucinogens and depressants) based on the features seen with acute unwanted 
effects; more recently with the evolution of the NPS they have often been considered 
in four, somewhat overlapping functional categories related to their chemical 
structure, and psychopharmacological desired and unwanted effects: stimulants, 
cannabinoids, hallucinogens and depressants29-30. 
 
 This narrative review paper aims to provide a robust overview of the current trends 
and developments with NPS, including their chemical structures, mechanism of 
action, modes of use, intended intoxicant effects, and their associated physical and 
mental health harms. The current challenges faced by laboratory testing for NPS is 
also explored. The paper will adopt the ‘four category’ classification, with the caveat 
that some new compounds do not neatly fit into these and their effects cross these 
boundaries. However, it is the authors’ experience that this model provides a 
utilitarian framework, especially for the generalist and clinician, who can often find 
the scale and rapidity of change in the field of NPS overwhelming. Inevitably, in a 
paper of this scope, there are limitations to the amount of information that can be 
provided about individual compounds. References on further reading will be provided 
for the interested reader. A final caveat is that some authorities and experts do not 
typically consider the compounds nitrous oxide and ketamine to fall under the 
definition of NPS; they do fall within the UNDOC definition, and thus the authors 
have kept them within this piece. 
 
Synthetic Stimulants 
Synthetic stimulants comprise of a diffuse group of base compounds, which include 
cathinones, aminoindanes, phenethylamines, piperazines, and tryptamines, of which 
synthetic cathinones are by far the largest group and the most studied31. Currently, 
they represent the largest group of NPS that are monitored by the UNODC17 and 
EMCDDA18. They are designed to replicate the effects of traditional stimulant 
controlled drugs, such as cocaine, MDMA, and amphetamines32. They can be made 
into a variety of formulations and be insufflated, swallowed (often wrapped in paper, 
known as “bombing”), inhaled, smoked, injected or used rectally, the most common 
route being taken in pill/tablet form33. Synthetic stimulants promote an increase in 
synaptic availability of neurotransmitters, mainly dopamine (DA) and serotonin 
(5HT).  DA plays an important role in motivation, arousal, learning and reward, 
whereas  5HT is a contributor to feelings of happiness and a sense of emotional 
connectedness (‘entactogenic’)34. Synthetic stimulants act on the two 
neurotransmitter systems to different extents, accounting for their differing range of 
desired and unwanted effects28,35. These include sought after experiences such as 
euphoria, increased feelings of empathy and compassion, sense of inner peace and 
relaxation, enhanced self-confidence, sociability and libido, and boosted energy and 
alertness35,36. Synthetic stimulants have also been associated with adverse effects 
such as high addiction potential, severe intoxications linked to cardiac, metabolic, 
neuropsychiatric and neurological complications and an increasing number of 
fatalities37-39. 
 
Chemical structures 
Common first generation synthetic cathinones (natural cathinone being the main 
psychoactive compound found in khat leaves) include methcathinone, 4-
methylmethcathinone (mephedrone, 4-MMC, and first developed in the 1920s), 3,4-
methylenedioxy-N-methylcathinone (methylone) and 3,4-
methylenedioxypyrovalerone (MDPV) followed by a second generation consisting of 
4-methyl-N-ethylcathinone (4-MEC), 4-fluoromethcathinone (flephedrone, 4-FMC), 
its positional isomer 3-fluoromethcathinone (3-FMC) and α-PVP (α-
pyrrolidinopentiophenone). Synthetic cathinones are similar in structure to 
amphetamine type stimulants and are chemically referred to as β-ketone analogues 
because of the carbonyl (=O) group in β carbon40,41. The common pharmacophore 
group responsible for the psychoactive effect observed in synthetic stimulants is 
phenethylamine42, and it’s derivatives are reported to represent at least 37% of the 
NPS available on the illicit drug market43.  
 
Synthetic stimulants structurally similar to pyrovalerone (a psychoactive drug once 
used in the treatment of chronic fatigue and lethargy)44 such as MDPV, are highly 
lipophilic compared with other synthetic stimulants, and so have a high blood-brain 
barrier penetration and volume of distribution, resulting in longer plasma and tissue 
half-lives45,46. The presence of electrophilic groups such as fluorine also increases 
the lipophilic nature of synthetic stimulants analogues thereby making them more 
potent, a quality sought after by users who want to experience the ultimate new 
“party drug” which is more potent, longer acting and delivers a better “high”47. 
 
Mechanism of action 
Synthetic stimulants increase the monoamine neurotransmitters  DA and 5HT and to 
a lesser extent noradrenaline (NE) concentration in the synaptic cleft, which then 
mediate the stimulatory effects48. Two distinct mechanisms are responsible for the 
increase in monoamine concentration in the synaptic cleft. Firstly there is stimulation 
of non-exocytotic neurotransmitter release by inhibiting the vesicular monoamine 
transporter-2 (VMAT2) and reversing the transporter influx, thereby stimulating 
neurotransmitter release from the cytosolic pool or synaptic vesicles49. Secondly, 
there is inhibition of the uptake of neurotransmitters from the synaptic cleft by 
inhibiting the plasma membrane transporters, which are responsible for the uptake of 
DA, 5HT and NE 50-53. 
 
Harms and Adverse Effects 
Historically synthetic stimulants were developed to treat patients with Parkinsonism, 
obesity, or depression, but these were soon withdrawn due to concerns regarding 
their abuse and harm potentials54,55.Some have recently been reported to have been 
used as cognitive enhancers or ‘nootropics’ (classically to help students with their 
exams, with some reports of professionals using them to maintain attention at work 
in stressful environments)56 and as part of weight loss regimens57. The acute 
physical and mental health harms associated with the use of synthetic stimulants are 
due to sympathomimetic toxicity, which may present as agitation, nausea, vomiting, 
headache, palpitations, tachycardia, hypertension and hyperthermia, and less 
frequently as paranoia, hallucinations, seizures and collapse58. Less commonly, 
severe adverse effects such as significant peripheral organ damage and 
rhabdomyolysis have been reported, whilst deaths have been linked to hypertensive 
crises, hyperthermia, cardiac arrest, and/or serotonin syndrome59. Functional 
magnetic resonance imaging (fMRI) of rodents has shown that administration of 
MDPV results in desynchronisation of functional connectivity between the pre-frontal 
cortex and striatum, nucleus accumbens and the insular cortex60. More recent in-
vitro studies in neuronal, skeletal muscle and hepatic cells have demonstrated 
potentially cytotoxic effects of synthetic stimulant exposure, including mitochondrial 
dysfunction, glutathione depletion, oxidative stress, and apoptosis pathway 
activation, which are aggravated under hyperthermic conditions; however the extent 
to which these mechanisms are relevant to their effects in-vivo remains unclear60-62. 
 
Case reports have shown synthetic stimulants can induce acute intra-parenchymal 
and subarachnoid haemorrhages as well as ischemic infarction62, and α-PVP has 
been implicated in ST-elevation myocardial infarction (STEMI) with multiple intra-
cardiac thrombi63. Intravenous methcathinone (M-CAT) use has been associated 
with the rare syndrome of manganese-associated Parkinsonism (as the preparation 
of M-CAT involves use of potassium permanganate) and cognitive impairment, which 
has been termed “ephedrone encephalopathy”. Persistent globi pallidi 
hyperintensities on T1-weighted MRI have also been reported in those with this rare 
syndrome, and M-CAT use for longer than six months correlated with significant 
disability that did not improve despite drug cessation64.  
 
A number of public health concerns associated with synthetic stimulants have been 
highlighted. The growing practice of “slamming” during ChemSex (sexual activity 
engaged with multiple partners and often without protection, while under the 
influence of stimulant drugs, often with co-use of drugs such gamma-
hydroxybutyrate (GHB) and related analogues) in which mephedrone and/or other 
stimulants are injected to enhance sexual activity has raised concerns regarding 
substance use disorders, and increased risk of injection site injury, blood borne virus 
transmission, and sexually transmitted diseases65. In Scotland, an increase in 
injection of NPS, including synthetic stimulants, was associated with contiguous 
increases in HCV infection66. Synthetic stimulants have been found in a number of 
products claiming to enhance “brain health” and cognitive ability67, and those 
targeting athletes wanting to improve their performance68. Those with a diagnosis of 
ADHD have increasingly turned to the internet to source synthetic stimulants to help 
with their symptoms69,70. The harmful interactions between synthetic stimulants and 
prescription drugs, increasing the risk of drug toxicity or reducing the therapeutic 
efficacy of the drugs has also been highlighted71. 
 
Synthetic Cannabinoids 
Synthetic cannabinoids emerged in the mid-2000s and were first formally identified 
and reported to the EMCDDA in 2008, initially being used as alternatives to herbal 
cannabis, particularly to avoid detection in those settings with forensic drug testing 
regimes such as prisons, sports programmes, and the military72.  They have since 
proliferated worldwide in many different structures, forms and potencies, and 
currently represent the largest and most structurally diverse class of NPS73-74. The 
UNODC have reported approximately 280 synthetic cannabinoids had been 
identified by the end of 201975. They are typically manufactured and transported from 
producer countries as bulk powders, and, after dissolving in solvents such as 
acetone or methanol, are most commonly sprayed onto inert plant material 
(resembling traditional cannabis) or paper (to minimise risk of detection and facilitate 
access to forensic settings such as prisons) and either mixed with tobacco or 
smoked directly - inhalation being the main route of use76. Synthetic cannabinoids 
have been missold (e.g. as delta-9-tetrahydrocannabinol (d9-THC) or cannabidiol 
(CBD)), and have been detected in formulations such as powders and as liquids for 
use in vaping devices, or tablets and capsules resembling ecstasy77.  
 
Synthetic cannabinoids interact with the endocannabinoid system, which is involved 
in various physiological functions, including cognition, motor control, pain sensation, 
appetite, cardiovascular and respiratory performance, gastrointestinal motility, and 
immunoregulation78. Positive experiences from use include relaxation, euphoria, and 
disinhibition, which are similar to the desired effects of d9-THC, the main 
psychoactive component of traditional cannabis79.  
 
However synthetic cannabinoids are associated with a wide range adverse effects, 
including cardiovascular and respiratory complications, haemodynamic 
embarrassment, renal injury and cerebrovascular accidents (“strokes”)80-84.There 
have been numerous reports of severe morbidity and mortality from synthetic 
cannabinoids , especially from use in prisons and other secure settings and in 
people who are homeless85-90. In England and Wales, synthetic cannabinoids 
comprised the largest proportion of NPS-related poisoning deaths in 201890, with 
large outbreaks of intoxications also being reported in Europe91. 
 
Chemical Structures 
The main classes of synthetic cannabinoids can be divided into the following major 
chemical classes: classical cannabinoids, carbazoles, cyclohexyl-substituted 
phenols, naphthoylindoles, the URB-class and benzoylindoles24,92. New synthetic 
cannabinoids are regularly developed by both legitimate and clandestine chemists, 
and these differ by the addition or removal of a substituent group93, making the 
pharmacological profiles of new compounds entering the market difficult to predict 
and monitor94.  Synthetic cannabinoids demonstrate limited structural similarity to d9-
THC, and are referred to as synthetic cannabinoids due to their pharmacological 
mechanisms95. Therefore, unless specifically included in reference databases they 
will typically not be detected in conventional drug screening procedures such as 
urine tests96.  
 
Mechanism of Action 
Synthetic cannabinoids interact primarily with the endocannabinoid system, and its 
two specific G protein-coupled receptors: predominantly with the cannabinoid 
receptor type‐1 (CB1) and less frequently with the cannabinoid receptor type‐2 
(CB2). The CB1 receptor is widespread throughout the brain, with particular 
concentration in the neocortex, basal ganglia and hippocampus, where they 
modulate pre‐synaptic neurotransmitter release, and participate in a variety of brain 
function modulations, including executive, emotional, reward, and memory97,98. The 
CB2 receptor, initially thought to be confined to immune cells and peripheral tissues, 
has recently also been found in cerebellum and brain stem neurons, where their 
roles remain an issue of active research99. Research into how synthetic 
cannabinoids modulate their effects via these receptors and the difference between 
the observed clinical effects of traditional cannabis and synthetic cannabinoids is 
ongoing, but current hypotheses include biased signalling at cannabinoid receptors 
or the disruption of mitochondrial homeostasis. Synthetic cannabinoids do not 
contain cannabidiol (the main neuro-protective compound found in natural cannabis 
which predominantly acts on CB2 receptors) and this may also be related to the 
increased toxicity observed with these compounds compared to natural 
cannabis100,101. 
 
Synthetic cannabinoids have a greater potency and binding affinity than d9-THC at 
the cannabinoid receptors. They are full agonists compared with the partial agonist 
properties of d9-THC, with potency of 10 to 200 times greater than that of d9-THC. 
These differences likely underpin the emerging greater incidence of major psychiatric 
complications and other adverse effects compared to traditional cannabis101-104. A 
self-reported survey of 80,000 illicit substance users revealed that those who used 
synthetic cannabinoids were thirty times more likely to end up in an emergency 
department than users of traditional cannabis83. 
 
Harms and Adverse Effects 
There is currently no evidence for any therapeutic potential of synthetic cannabinoids 
with overwhelming reports of mild to severe adverse effects105. Most common mild to 
moderate adverse effects include nausea, protracted vomiting, agitation, drowsiness, 
dizziness, confusion, hypertension, tachycardia and chest pain, which typically have 
a limited duration and require only supportive treatment. There is growing evidence 
that renal injury is associated with a direct toxic effect upon the kidneys rather than 
an indirect effect due to dehydration (caused by vomiting) as was previously 
thought106-7. A wide range of serious physical health harms associated with synthetic 
cannabinoid use has also been reported. These include convulsions and seizures108, 
rhabdomyolysis and hyperemesis syndrome109,110, supraventricular and ventricular 
arrhythmias111,112, pulmonary embolism112,113, intracranial hemorrhage114, delirium 
and multiple organ failure109,115.Serious mental health harms include paranoia, 
psychosis, aggression and violence towards others, self-harm and suicide. A trend of 
synthetic cannabinoid related toxicity has also been observed, with first generation 
compounds predominantly presenting with cannabis like unwanted effects, second 
generation compounds with cardiovascular/stimulant toxicity and third generation 
compounds with neurological toxicity associated with central nervous system 
depression116-120.  
 
Synthetic cannabinoid use has been associated with white matter abnormalities in 
adolescents and young adults, which may lead to cognitive impairment and 
vulnerability to psychosis121. MRI brain changes associated with synthetic 
cannabinoid toxicity reveal diverse findings, including embolic stroke, global hypoxic-
ischaemic brain injury, demyelinating injury, and leptomeningeal enhancement122. 
These varied imaging findings may reflect the diverse actions of the 
endocannabinoid system, including its role in the regulation of cerebral perfusion, 
inflammatory responses and mitochondrial function74. Synthetic cannabinoids have 
been implicated in executive-function impairment either after acute or repeated 
consumptions123. Intense psychological withdrawal syndromes after use have also 
been described leading to a high addictive potential for synthetic cannabinoids, 
where users have been reported to use synthetic cannabinoids every thirty minutes 
to avoid feeling unwell124-6.  
 
Public health concerns have been raised around the use of synthetic cannabinoids in 
vaping devices or water pipes and the subsequent development of serious lung 
injuries including acute respiratory distress syndrome and the diffuse alveolar 
haemorrhage127. Termed EVALI (e-cigarette, or vaping, product use–associated lung 
injury), recent reports have highlighted the increasing association with either lipoid 
pneumonia, chemical pneumonitis or an organising pneumonia leading to respiratory 
complications including death127,128. 
 
Synthetic Hallucinogens 
Synthetic hallucinogens (SH) include two main subcategories: hallucinogens and 
dissociatives. 
 
 
 
Hallucinogens 
Hallucinogens are typically further sub-divided into three classes: tryptamines, 
lysergamines and phenethylamines129. Most hallucinogens share a common 
mechanism of 5-HT2A receptor modulation of serotoninergic activity, although there 
is an increasing understanding of the role of the glutamatergic system, and some 
dissociative hallucinogens also have activity at κ opioid receptors130.  Routes of use 
include inhalation, nasal insufflation, oral ingestion (pill or blotter paper), 
sublingual/buccal administration, and intravenous injection131-133. 
 
Distributed throughout the brain and spinal cord, serotonin is involved in the control 
of a wide range of behavioural, perceptual, and regulatory systems, including mood, 
hunger, body temperature, sexual behaviour, muscle control, and sensory 
perception. Common sought after experiences include euphoria and joy, alterations 
in time/space perception, increased creativity and insight, accelerating and 
broadening thought processes and content, promoting novel thought associations, 
and providing psychedelic, spiritual and mystical experiences134. Common adverse 
effects include complications associated with serotonergic and sympathomimetic 
toxicity135, and a broad range of mental health crises136.  
 
Chemical structure 
The largest group of synthetic hallucinogens are the phenethylamine derivatives 
which are 2,5-dimethoxyphenethylamines, and contain a small lipophilic substituent 
at the 4-position, known as the 2C series because they possess two carbon atoms 
between the benzene ring and amino group137. Further derivatives are mostly but not 
exclusively chemically modified at the phenyl ring. The introduction of an N-
benzylmethoxy (‘‘NBOMe’’) group has resulted in an increase the potency of 
derivatives138.  
 
Tryptamines are a group of monoamine alkaloids that are synthesised through 
decarboxylation of the amino acid tryptophan, and include compounds such as  
alpha-methyltryptamine (AMT), N,N-dimethyltryptamine (DMT), N,N-diallyl-5-
methoxytryptamine (5-MeO-DALT) and 5-methoxy-N,N-disopropyltyptamine (5-MeO-
DIPT) “foxy methoxy”. They possess an indole ring structure, a bicyclical 
combination of a benzene ring and a pyrrole ring, with an amino group attached to a 
2-carbon side chain139.  
 
Synthetic derivatives of the ergot alkaloid derivative lysergic acid diethylamide (LSD) 
such as 1-acetyl-LSD (ALD-52), 1-propionyl-LSD (1P-LSD), and 1-butyryl-LSD (1B-
LSD) have been shown to have very different pharmacological profiles and may 
differ significantly in their effects140,141. 
  
Mechanism of action 
Phenethylamine derivatives mainly interact with cortical serotonin receptors, with the 
highest affinity for 5-HT2A receptors142. NBOMe derivatives have higher affinity for 5-
HT2A and 5-HT2C receptors and lower affinity for 5-HT1A receptors compared with 
their 2C- analogues. Tryptamine derivatives have an affinity for 5-HT1A, 5-HT2A, 
and 5-HT2C receptors and can inhibit reuptake and increase the release of 
serotonin139. LSD analogues activate both 5-HT2A and 5-HT1A receptors143. 
Activation of 5-HT2A receptors causes glutamate release and activation of alpha-
amino-3-hydroxy-methyl-5-4-isoxazolpropionic (AMPA) glutamatergic receptors, thus 
increasing cortical activity and information processing144. 
  
 
Harms and adverse effects 
Over the last fifty years, there has been ongoing interest and research into the use of 
the hallucinogen base compounds and their synthetic derivatives in the treatment of 
anxiety, depression and substance misuse disorders, and as an adjunct in 
psychotherapy. Data are currently encouraging, but lacking adequate evidence for 
use outside of scientific trials at this time145-8. 
 
Common adverse effects primarily reported in studies of non-clinical use, shared 
across all three classes include tachycardia, hypertension, mydriasis, hyperthermia, 
agitation, aggression, hallucinations, drowsiness and confusion149-153. More serious 
adverse effects associated with phenethylamine derivatives, include multi-organ 
failure, psychosis, seizures, and serotonin syndrome150. Serious adverse effects of 
tryptamine derivatives include prolonged delusions150, rhabdomyolysis and renal 
failure155 and a number of reported fatalities156. LSD derivative adverse effects 
include impaired thermoregulation, cardiovascular instability, difficulty concentrating, 
imbalance and exhaustion157. 
 
Case reports have highlighted serious but relatively uncommon complications 
associated with toxicity of synthetic hallucinogens including an “excited delirium” 
picture with severe agitation, aggression, and violence158, hyperreflexia and 
clonus130 and acute pulmonary oedema and hyperthermia leading to death159. 
 
Dissociatives 
The two main classes of dissociatives are arylcyclohexylamine (to which ketamine, 
phencyclidine (PCP) and methoxetamine (MXE) belong) and diarylethylamine. PCP 
was first synthesised in 1956 as an anaesthetic but largely withdrawn from frontline 
use because of its unfavourable side effects and abuse potential. Ketamine remains 
an important medicine in both specialist anaesthesia and aspects of pain 
management and is currently being studied as a rapid-acting antidepressant160. Both 
classes of dissociatives act as antagonists on the N-methyl-D-aspartate receptor 
(NMDAR)161.  
 
Routes of use include inhalation, nasal insufflation, oral ingestion and intravenous 
injection162. The sought after experiences include the sense of a disconnection 
between thoughts, identity, memory and consciousness, as well as sensory and 
tactile distortions, euphoria, and depersonalisation. Common serious adverse effects 
include neurological impairment, renal and bladder injury163. 
 
Chemical structure 
All first-generation dissociatives are simple derivatives of PCP. The 
arylcyclohexylamine structure contains three distinct regions: an aromatic ring, a 
substituted cyclohexane ring, and a basic amine function. The first-generation 
dissociatives involved an aryl or amino substitution, without alteration of the 
cyclohexane ring. Retention of the cyclohexane ring provides for NMDAR affinity and 
therefore potency164. The latest generation of dissociatives, diarylethylamines, 
include 1-(1,2-diphenethyl) piperidine (diphenidine) and 1-[1-(2-methoxyphenyl)-2-
phenylethyl] piperidine (2-MeO-diphenidine), and are also similar in structure to 
PCP165. 
Mechanism of action 
Similar to ketamine and PCP, dissociative arylcyclohexylamine and diarylethylamine 
drugs act as relatively selective non-competitive antagonists at the ionotropic 
glutamatergic NMDAR. Their NMDAR affinity is strongly correlated with their clinical 
potency in producing dissociative effects The NMDAR channels play an important 
role in synaptic plasticity and synapse formation underlying memory, learning and 
formation of neural networks during development in the central nervous system166. 
Ketamine has a predominant action at the NMDA receptors whereas PCP, 
methoxetamine, 3-MeO-PCP, 4-MeO-PCP and 3-MeO-PCE have actions at 
serotonin receptors which may explain some of their additional toxicity167. 
 
Harms and adverse effects 
Current research into the use of dissociatives in the treatment of a number of 
conditions is ongoing, including depression, pain management and palliative 
care168,169. Common adverse effects shared across both classes include nausea, 
diaphoresis, hypertension, tachycardia, renal impairment, agitation, disorientation, 
confusion, nystagmus, slurred speech, hallucinations, amnesia, ataxia, and muscle 
rigidity170. Serious adverse effects include cerebellar toxicity, rhabdomyolysis, severe 
kidney and bladder damage and a number of fatal intoxications171. 
 
In-vitro studies have shown MXE to potently inhibit neuronal activity and alter 
monoamine metabolism172. Repeated parenteral administration of mMXE stimulates 
the mesolimbic dopaminergic transmission in rats, and affects brain functions and 
behaviour173. A similar study found that repeated parenteral administrations of MXE 
induced anxiety-like states and interfered with memory174. The same investigation 
also demonstrated that MXE induced persistent damage of dopaminergic neurons in 
the nigrostriatal and mesocorticolimbic systems, as well of serotonergic neurons in 
the nucleus accumbens core174. MXE use by humans has been associated with 
acute neurological impairment including psychomotor agitation and altered motor 
coordination175, and chronic bladder and urinary tract toxicity reported in mice176. 
 
Case reports have reported serious adverse effects including seizures, 
hyponatremia, and sinus bradycardia177, neurological impairment with significant 
cerebellar toxicity178 and a number of fatalities associated with intoxication179-83. 
Synthetic Depressants 
Synthetic depressants are broadly classified into two sub-categories, synthetic 
benzodiazepines and synthetic opiates. Their acute emergency presentations can 
appear similar – thought treatments are different - but they differ in their impact on 
mental health26. Furthermore, among high-risk opioid users, benzodiazepines, 
especially when injected, can prolong the intensity and duration of the opioid 
effects184. 
 
Synthetic benzodiazepines. 
Synthetic benzodiazepines are commonly consumed for non-medical purposes. 
Primary motivations for use overlap with clinical utility, such as hypnotic and 
anxiolytic effects, and to manage the acute effects of stimulants or to self-treat 
withdrawal symptoms, but they also produce a subjective “high”185 . Reports on 
internet forums also suggest that users experience anticonvulsant, muscle relaxant, 
and amnesic properties186. 
 
Chemical structure 
The base structure is the fusion of a benzene ring and a diazepine ring, individual 
compounds varying widely according to additions to the base structure, e.g. 2-keto 
compounds (diazepam), 3-hydroxy compounds (temazepam), 7-nitro compounds 
(clonazepam), Triazolo compounds (alprazolam) and Imidazo compounds 
(midazolam)187. 
 
Mechanism of action 
A contemporary hypothesis is that novel benzodiazpeines mediate their effects 
through interactions at gamma-aminobutyric acid-A (GABA-A) receptors similar to 
prescription benzodiazepines188. GABA-A receptors are ion channels that consist of 
different subunit compositions, responding to the inhibitory neurotransmitter GABA.  
Synthetic benzodiazepines may enhance the effects of GABA as positive allosteric 
modulators by binding to a receptor site that is different from the binding site of 
GABA 187,189, resulting in sedative, hypnotic (sleep-inducing), anxiolytic (anti-anxiety), 
anticonvulsant, and muscle relaxant properties. Another mechanism of action 
reported includes activation of the mitochondrial translocator protein (TSPO) 18 kDa, 
which stimulates synthesis of neuroactive steroids, including allopregnanolone. 4-
chlorodiazepam (Ro 5-4864) binds to this protein instead of GABA-A receptor, 
leading to anxiogenesis and an increased risk of seizures190. Some synthetic 
benzodiazepines have also been found to activate the AMPA glutamate receptor, 
leading to the rapid opening and closing of an ion channel that is permeable to 
cations (sodium, calcium and potassium); if inhibited this results in an inhibition of 
central nervous system fast excitatory synaptic transmission. Tofisopam is a 
competitive antagonist at this receptor (and doesn’t have GABA-A activity) and may 
cause anxiolytic actions without the sedative effects seen with other 
benzodiazepines191. 
 
Harms and adverse effects 
Data on the effects and harms of new synthetic benzodiazepines remains somewhat 
limited at this time, but early studies have shown anxiolytic, anticancer, 
anticonvulsant, antipsychotic, muscle relaxant, anti-tuberculosis, and antimicrobial 
actions192,193. 
 
Adverse effects include a sedative-hypnotic toxidrome and can include confusion, 
dizziness, drowsiness fatigue, as well as auditory and visual hallucinations, delirium, 
seizures, deep sleep, and coma184 and atypical symptoms such as agitation, 
hyperthermia, and tachycardia194. Abrupt cessation may lead to withdrawal 
symptoms, such as anxiety, panic attacks, restlessness, insomnia, and 
convulsions195. A number of fatalities have been reported, as well as the added risk 
in relation to toxicity due to the slower onset of action and longer half-life of some of 
the synthetic benzodiazepines (slower onset users take more doses than required; 
longer half-life toxicity is more prolonged)196-199. Bentazepam has been associated 
with chronic hepatitis200 
 
Synthetic Opioids 
Opioids include opiates, semi-synthetic opioids and synthetic opioids. Opiates are 
natural substances that originate from papaver somniferum (opium poppy), which 
contain more than twenty different subtypes201. Two of these, morphine and codeine 
are two of the most common pain medications prescribed202. Synthetic opioids are 
created to bind to the same receptors in the brain as opiates, and produce similar 
effects such as euphoria, anxiolysis, feelings of relaxation, and drowsiness. 
Undesirable side effects include nausea, dizziness, constipation, vomiting, tolerance, 
and respiratory depression203.  
 
The international opioid drug deaths epidemic is a source of much research and 
debate, but an examination of this is outside the scope of this review, and will be 
covered in a linked paper203-6. In Europe, 49 new synthetic opioids were detected 
between 2009 and 2018, 34 of which were fentanyl derivatives18. Whilst fentanyl 
itself is subject to international control, only some derivatives (e.g. carfentanil) are 
subject to international control at the time of writing.  Recent evidence points to a 
problematic surge in the availability of heroin mixed with fentanyl (cheaper and 
easier to obtain than pure heroin) leading to an increased risked of morbidity and 
mortality for the user, who is normally unaware of the addition of the synthetic 
opioid207-9. 
 
Chemical structure 
The chemical structure of opioids is subdivided into those based the 4,5-
epoxymorphinan ring (e.g. morphine), the phenylpiperidines (e.g. fentanyl) and the 
diphenylheptylamines (e.g. methadone). Synthetic opioids are modifications of each 
of these base compounds210.  
 
Mechanism of action 
Synthetic opioids analogues interact with G protein-coupled opioid receptors in the 
brain and spinal cord as partial to full agonists at mu, delta and kappa opioid 
receptor subtypes, with selectivity for the mu opioid receptor211-212. Agonism at mu 
opioid receptors is responsible for the main pharmacological effects of opioids, 
including euphoria, analgesia, respiratory depression, as well as the development of 
dependence213. Many synthetic opioids are considerably more potent than traditional 
opioids. The potency of fentanyl (acting on the mu opioid receptor) is 50 to 200 fold 
higher than morphine, and that of carfentanil (also on the mu opioid receptor) 
approximately 10,000 times higher than morphine211,214. 
 
 
 
 
Harms and adverse effects 
Synthetic opioid adverse effects range from mild (pruritus, nausea, vomiting, 
constipation, dizziness) to severe (respiratory depression, apnoea, and central 
nervous system depression)215-6. Intoxication with synthetic opioids has been 
associated with non-cardiogenic pulmonary oedema, acute lung injury, diffuse 
alveolar haemorrhage and rhabdomyolysis217-8. Withdrawal from synthetic opioids 
may present with physiological and psychological distress219. Statistics on morbidity 
and mortality may not reflect the real life situation as users may recover, for 
example, from a mixed heroin/synthetic opioid overdose when naloxone is 
administered and the illicit drug documented will then be heroin and not a synthetic 
one220-1. In the STRIDA project from Sweden, it was reported that there were a 
number of cases of toxicity related to the use of MT-45 (a synthetic opioid) that in 
addition to typical opioid like toxicity was also associated with hearing loss and/or 
deafness222-3. 
 
Laboratory testing 
Testing for NPS in clinical and forensic settings can be a complex task, as routine 
testing of such compounds in individuals who present with recreational drug toxicity 
is not typically undertaken, and the validity and reliability of test kits varies 
considerably in detecting these many new agents. Furthermore, in clinical practice 
patients are typically treated on the basis of the pattern of toxicity they present with, 
and the turn-around time for a standard and comprehensive NPS screen would often 
mean that the results are not available in a time-frame that would alter the clinical 
management of the patient19. Test designs also need to take into account that users 
of NPS will be likely to use additional over-the-counter medication, other illicit 
drugs224-5 and that NPS preparations themselves may be contaminated with other 
illicit drugs226, or dissolved in diluents227.  
 
The Novel Psychoactive Treatment UK Network (NEPTUNE) recognise the current 
limitations in the availability of timely clinical testing available during acute 
presentations of NPS toxicity, and currently recommend toxicity diagnoses are made 
primarily on clinical features, rather than by testing. However, NPS toxidromes may 
be highly non-specific (such as synthetic stimulant and synthetic cannabinoid 
toxicity), and, as noted, users may have taken multiple NPS or other substances 
simultaneously, making identification of a likely causative NPS class(es) from clinical 
features alone difficult. As such, reliable and clinically validated testing for NPS from 
human samples are clearly of value. Colorimetric tests, immunoassays, and mass 
spectrometry-based techniques have been employed in the detection of NPS. A 
recent systematic review reported that relatively few tests are able to detect more 
than 50 NPS types228. Colorimetric methods are based on a target compound 
reacting with a reagent to produce a detectable colour change. They are easy to use, 
portable, point-of-use tests, with limited need for sample pre-preparation. The 
disadvantages include user variability in detecting colour-changes, cross-reactivity 
(associated with false-positive results), in addition to the limited range of individual 
NPS compounds that may be tested for in a single sample228. 
 
Immunoassays for NPS allow for potentially rapid testing, and are suitable for testing 
non-invasively obtained samples (typically urine samples, or dissolved drugs). 
Lateral flow immune-chromatographic assays have been used in harm-reduction 
trials where opiate users were encouraged to self-test drugs for the presence of 
fentanyl229.  Commercially available immunoassays are limited to testing for relatively 
small selections of NPS. The sensitivity of commercially available immunoassay 
testing may also be limited, with a study of cross-reactivity amongst five 
commercially-available immunoassay kits reported to have failed to detect 13 of 94 
(14%) NPS samples tested230.   
    
Gas and liquid chromatographic mass spectrometry-based methods offer more 
sensitive and specific identification of individual NPS, and allow for quantification of 
NPS within biological samples. These techniques can allow for sampling across a 
range of biological samples, including blood, urine, hair231, saliva232, urban 
wastewater233 and dried blood samples234. Samples for analysis require laboratory 
pre-preparation before being used for these techniques, though so-called “dilute and 
shoot” techniques are being validated to allow for more rapid preparation of 
biological samples for liquid chromatography mass spectrometry235-6. Liquid 
chromatography with quadrupole time of flight mass spectrometry (LC-QTOF MS) 
has demonstrated some superiority to gas chromatography mass spectroscopy (GC 
MS) in detecting most forms of NPS within serum samples235. Databases of spectral 
information from known NPS chemical structures are currently being built and 
validated, to allow for identification of known (and potentially unknown) substances 
based on the technique used 236-7. 
 
Conclusion 
NPS comprise a diverse and ever growing group of substances. There is much we 
still do not know, especially about the newest agents, and they can vary considerably 
in their desired effects and harms, even within drug classes. The classification 
system that has been used for this review has arisen for reasons of practicality and 
clinical utility, though this means that it inevitably has some limitations. The currently 
used four separate classification system groups together compounds with highly 
varied chemical structures (such as the synthetic cannabinoids), or mechanistically 
heterogeneous compounds (such as the hallucinogens and depressants) in a 
practical workable system for clinicians, scientists, law enforcement agencies and 
other interested parties.   
 
Even with this broad classification system there remains considerable overlap 
between some groups of NPS (such as the 2-C series, 5-MeO DALT, and NBOMe- 
series), which may have characteristics in terms of their pharmacology, desired 
effects and/or unwanted effects that fit within more than one of the classification 
groups.  
 
Much of the literature on health effects of NPS is derived from self-reports, and small 
case series, which are very likely to be subject to a variety of selection and recall 
biases. Given the nature of NPS and their use, the reliance on small case series and 
self-reports is unsurprising. In the UK, national advisory bodies such as the Novel 
Psychoactive Treatment UK Network (NEPTUNE) and UK National Poisons 
Information Service (NPIS) are likely to be able to monitor trends of NPS use in a 
more rigorous and prospective manner. A network of emergency departments in 
Europe have collaborated to form the European Drug Emergencies Network Plus 
(EuroDEN-Plus) project, to better understand the pattern of toxicity associated with 
NPS clinical presentations238-241.    
 
Clearly there is a need for healthcare and emergency professionals that are likely to 
encounter NPS use to remain up-to-date with clinical features of NPS use, and 
evidence-based approaches to harm-minimisation and treatment of dependence 
syndromes need to be developed. These should ideally be developed in conjunction 
with the experiences of NPS users themselves. Whether the current popularity of 
NPS use will continue remains uncertain, and there is comparatively little evidence 
regarding NPS use in lower- or middle- income countries, where NPS use may be 
particularly likely to be associated with societal harm.  
 
Clinicians treating individuals who present with harms related to the use of NPS may 
feel less confident in managing those patients compared to patients who present 
following the use of classical recreational drugs242. However, since the management 
of both groups of individuals is typically based on the presenting clinical features 
rather than the specific drug(s) involved, clinicians should feel more confident in 
utilising the knowledge, skills and experience in managing classical recreational 
drugs to any individual who presents with acute recreational drug/NPS toxicity. 
 
Further research is needed on the neuropsychological consequences of NPS use, 
given the apparent neurotoxic effects associated with NPS use. Recently developed 
novel radiotracers for use in positron emission tomography (PET) for CB1 and CB2 
receptors, as well as hydrolytic enzymes of the endocannabinoid system, may be of 
use in identifying changes in vivo in those with sustained and acute synthetic 
cannabinoid (and other NPS) use243. 
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